This week, Israel-based Protalix BioTherapeutics, Inc, announced positive results from a phase 2 clinical trial for its orally administered anti–tumor necrosis factor (anti-TNF) drug, OPRX-106, a plant cell–expressed recombinant human TNF receptor II fused to an IgG1 Fc domain.
This week, Israel-based Protalix BioTherapeutics, Inc, announced positive results from a phase 2 clinical trial for its orally administered anti—tumor necrosis factor (anti-TNF) drug, OPRX-106, a plant cell–expressed recombinant human TNF receptor II fused to an IgG1 Fc domain.
Protalix says that OPRX-106 met its key efficacy endpoints in the open-label, 2-arm study of OPRX-106 in 24 patients with mild to moderate ulcerative colitis (UC). Among the patients, who were randomized to receive oral administration of either 2 mg or 8 mg of the study drug once daily for 8 weeks, 67% experienced a clinical response and 28% achieved clinical remission.
Other key efficacy endpoints were also met, with 72% of patients showing improvement in rectal bleeding scores, 72% of patients demonstrating an improvement in fecal calprotectin, and 61% of patients showing an improved Gebos score (a histopathological scoring for the assessment of disease activity in UC).
At week 8, improved Mayo scores were observed in 89% of patients, with an average decrease in Mayo score of 45%—or 3 points—from baseline. No anti-drug antibodies were detected, and Protalix says that only mild to moderate adverse events were reported, with headaches being the most common.
“We are very excited by these results,” said Moshe Manor, president and CEO of Protalix. “They demonstrate efficacy and a lack of immunogenicity together with a favorable safety profile, which could potentially overcome one of the most challenging drawbacks of current ulcerative colitis therapies administered via injection and infusion.”
In January 2018, the company reported positive interim data from the first 14 patients to complete 8 weeks of treatment. The interim data demonstrated that 57% of patients achieved clinical response at week 8 and 36% achieved clinical remission.
Protalix is not the first to attempt to deliver anti-TNF therapy in an oral administration; in 2016, Avaxia Biologics reported positive results of a first-in-human trial of its AVX-470, a polyclonal bovine-derived anti-TNF drug, in patients with UC, saying that the agent was safe and well tolerated in the trial. However, Circle33 LLC, which later acquired Avaxia’s patents for the drug, has not reported any further developments.
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
Biosimilar and Biologic Use Increasing in Greek Patients With IBD
April 19th 2025A retrospective study from a single inflammatory bowel disease (IBD) center in Greece reported that from 2018 to 2022, the use of biologics increased by 28% yearly, and the proportion of patients using biosimilars grew from 33% to 67%.